
-
PMV Pharma NasdaqGS:PMVP PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Location: 400 Alexander Park Drive, Princeton, NJ, 08540, United States | Website: https://www.pmvpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-112.8M
Cash
160.4M
Avg Qtr Burn
-13.34M
Short % of Float
2.54%
Insider Ownership
3.23%
Institutional Own.
78.19%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rezatapopt/ PC14586 (p53 reactivator) Details Solid tumor/s, Cancer | Phase 2 Data readout | |
Rezatapopt/ PC14586 (p53 reactivator) +/- azacitidine Details Cancer, Blood cancer, Acute myeloid leukemia | Phase 1b Data readout | |
Rezatapopt/ PC14586 (p53 reactivator) + KEYTRUDA Details Solid tumor/s, Cancer | Failed Discontinued |